Apply to trial NCT07678684

A few quick questions so the study team can decide if you might be a fit.

RecruitingPhase 2Drug trial

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

The primary purpose of this Phase II study is to evaluate the preliminary anti-tumor efficacy of HF1K16 in combination with Bevacizumab in patients with recurrent or progressive glioma. The study also evaluates the safety and tolerability of the combination therapy.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening